Bojestig 2001

Methods	Country: Sweden Setting/Design: Multicentre Time frame: NS Randomisation method: NS Blinding ‐ Participants: Yes ‐ Investigators: Yes ‐ Outcome assessors: No ‐ Data analysis: No Intention‐to‐treat: Yes Follow‐up period: 24 months Loss to follow‐up: 1
Participants	Inclusion criteria Normotensive patients (BP < 90 mm Hg) with microalbuminuria (20‐200 µg/min) in 2 of 3 urine collections Ramipril group 1 Number:19 Age: 42 (10) Sex (M/F):13/6 Ramipril group 2 Number: 18 Age: 39 (10) Sex (M/F): 14/4 Placebo group Number: 18 Age: 38(9) Sex (M/F): 14/4 Exclusion criteria Patients treated with any form of antihypertensive medication
Interventions	Ramipril group 1 1.25 mg/d Ramipril group 2 5 mg/d Placebo group Co‐interventions: No
Outcomes	ACE activity and PRA BP AER
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear